BIOMARKER:

Chr del(11q)

A2 | Sensitive

B | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

A2 | Resistant

B | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Multiple Myeloma

obinutuzumab + acalabrutinib

Chr del(11q)|Chronic Lymphocytic Leukemia|obinutuzumab + acalabrutinib

zanubrutinib

Chr del(11q)|Chronic Lymphocytic Leukemia|zanubrutinib

Chr del(11q)|Small Lymphocytic Lymphoma|zanubrutinib

ibrutinib + ublituximab-xiiy

Chr del(11q)|Chronic Lymphocytic Leukemia|ibrutinib + ublituximab-xiiy

ibrutinib

Chr del(11q)|Chronic Lymphocytic Leukemia|ibrutinib

Chr del(11q)|Small Lymphocytic Lymphoma|ibrutinib

orelabrutinib

Chr del(11q)|Chronic Lymphocytic Leukemia|orelabrutinib

Chr del(11q)|Small Lymphocytic Lymphoma|orelabrutinib

RP6530

Chr del(11q)|Chronic Lymphocytic Leukemia|RP6530

acalabrutinib

Chr del(11q)|Chronic Lymphocytic Leukemia|acalabrutinib

venetoclax + ibrutinib

Chr del(11q)|Chronic Lymphocytic Leukemia|venetoclax + ibrutinib

lenalidomide + tafasitamab-cxix

Chr del(11q)|Chronic Lymphocytic Leukemia|lenalidomide + tafasitamab-cxix

venetoclax

Chr del(11q)|Chronic Lymphocytic Leukemia|venetoclax

duvelisib

Chr del(11q)|Chronic Lymphocytic Leukemia|duvelisib

FCR

Chr del(11q)|Chronic Lymphocytic Leukemia|FCR

ibrutinib + UC-961

Chr del(11q)|Chronic Lymphocytic Leukemia|ibrutinib + UC-961

Compound C

Chr del(11q)|Chronic Lymphocytic Leukemia|Compound C

hydroxychloroquine

Chr del(11q)|Chronic Lymphocytic Leukemia|hydroxychloroquine

obinutuzumab

Chr del(11q)|Chronic Lymphocytic Leukemia|obinutuzumab

Chr del(11q)|Multiple Myeloma|obinutuzumab

rituximab

Chr del(11q)|Chronic Lymphocytic Leukemia|rituximab

MRT68921

Chr del(11q)|Chronic Lymphocytic Leukemia|MRT68921